MASTER Trial: Prospective, multicentre, randomized trial evaluating the MGuard stent in the treatment of patients with acute myocardial infarction with ST segment elevation (STEMI).

Foreword: The EPS MGUARD stent (embolic protection stent) has a fine metal structure covered by a thin polyethylene fiber mesh with pores of 5 microns wrapping the stent that might prevent distal embolization during primary angioplasty and would therefore be particularly attractive during primary angioplasty.

Methods and Results: We included 432 patients referred for primary angioplasty having 70% ST). In two thirds of the population we used a predilatation thromboaspiration catheter and predilatation reached 50%. The MGuard direct implantation was 12% and 10.6% in the conventional group (p = NS). The MGuard group had a higher rate of final TIMI III (91.7% versus 82.9%, p = 0.006) and ST resolution (57.8% versus 44.7%, p = 0.008). The MGuard group showed a tendency to have lower cardiac mortality at 30 days (0 versus 1.9%, p = 0.06), with no observed difference in the rate of reinfarction, thrombosis or emergency reintervention.

Conclusion: The MGuard stent in a primary angioplasty context is associated with a better rate of ST resolution and final TIMI III flow. Studies with a larger sample size are needed to confirm the preliminary results observed in this randomized study.

Read article

6_gregg_stone_slides
Gregg Stone.
2012-10-24

Original title: The MASTER Trial a prospective, randomized, multicenter evaluation of a PET Micronet Mesh Covered Stent (MGuard) in STEMI.

More articles by this author

PARTNER cohort B: Clinical events at 3 years follow-up in patients with

Background: Percutaneous aortic valve implantation (TAVI) is the treatment of choice for patients with severe aortic stenosis considered inoperable according to clinical outcomes at...

ETAP: Endovascular treatment of atherosclerotic popliteal artery lesions: a prospective, multi-center, randomized study.

Introduction: The popliteal artery is a vessel considered unfavorable for the implantation of a stent due to the forces exerted in the popliteal fossa...

ISAR-LEFT MAIN 2: Everolimus-eluting stents versus Zotarolimus eluting stents in the treatment of the unprotected left coronary trunk.

Summary: Second-generation drug-eluting stents have shown better results than their predecessors. In this study we compare two second-generation drug stents in patients with unprotected...

FAME 2: Cost-effectiveness of FFR-guided angioplasty in patients with stable angina

Introduction: FAME study 2, presented at the European Congress of Cardiology 2012, is a multicenter study that randomized patients with stable angina FFR-guided angioplasty...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...